1. Upregulation of adiponectin is involved in the cardioprotective effect of etanercept in myocardial ischemia/reperfusion (MI/R) mice
- Author
-
Sun Lu, Han Wang, Yi Liu, Jingyi Liu, Haichang Wang, Yunping Guo, Peilin Liu, Yang Lu, Lijian Zhang, Qiang Yang, Ling Tao, and Chao Gao
- Subjects
medicine.medical_specialty ,Adiponectin ,business.industry ,Pharmacology ,medicine.disease ,Surgery ,Etanercept ,Downregulation and upregulation ,Rheumatoid arthritis ,Conventional PCI ,medicine ,Tumor necrosis factor alpha ,Myocardial infarction ,Cardiology and Cardiovascular Medicine ,business ,Reperfusion injury ,medicine.drug - Abstract
Objectives Evidence exists that the increase of TNFα is associated with reperfusion injury in patients with myocardial infarction after PCI. Adiponectin (APN) is anti-inflammatory and cardioprotective protein suppressed by TNFα, and is significantly reduced during MI/R. Whether neutralising TNFα protects against MI/R injury through upregulation of APN level has not been previously investigated. Methods and Results Adult male C57 mice were subjected to 30 min MI followed by 3h or 24h reperfusion or sham MI/R for this study. Etanercept, a TNFα neutralising drug for treating rheumatoid arthritis in clinic, was intraperitoneally injected 10 min before reperfusion. Etanercept administration ameliorated MI/R injury evidenced by increased cardiac function (1 day, 7 day, 14 day p Conclusions Overall, we have demonstrated for the first time that upregulating of adiponectin is involved in the cardioprotective effect of Etanercept, suggesting that using a single administration of Etanercept during PCI might improve the outcome of myocardial infarction patients.
- Published
- 2011
- Full Text
- View/download PDF